ported the use of topical brimonidine, 0.33%, gel in controlling mild postoperative bleeding after Mohs micrographic surgery (MMS). Herein, we report 2 cases of altered mental status likely secondary to central nervous system (CNS) depression after the use of topical brimonidine, 0.33%, gel for hemostasis.
Report of Cases

Case 1
A man in his 70s presented for MMS of a 5-cm squamous cell carcinoma (SCC) on his right temple. His medical history was remarkable only for previously treated SCCs on his head and neck. On presentation, the patient was alert, oriented, and ambulatory.
A biopsy specimen from the first stage of MMS extended to the deep fat. Hemostasis was easily achieved using electrodessication. Histologic examination revealed persistent SCC involving all margins. A biopsy specimen from the second MMS stage was taken with a 3-to 4-mm margin, and the remaining tissue was excised down to the periosteum. A cumulative total of 9 cm 3 of lidocaine, 1%, with epinephrine 1:100 000 was used.
Ten grams of brimonidine, 0.33%, gel were applied under occlusion with telfa and gauze for hemostasis. Histologically, residual SCC was seen in the periosteum. Suddenly, the patient developed a sullen affect, and he expressed a sense of impending doom. The patient's mental status rapidly deteriorated, and he became completely obtunded within minutes. Placing the patient in Trendelenburg position did not provide improvement. Basic life support measures were initiated immediately, and the patient was transported to the hospital.
IMPORTANCE
Minor bleeding is the most common complication of dermatologic surgery. Topical brimonidine, 0.33%, gel has been reported for the use of hemostasis in dermatologic surgery. The safety profile and risk of systemic toxic effects when brimonidine is used topically for hemostasis is unknown.
OBJECTIVE To determine the risk of systemic toxic effects of topical brimonidine, 0.33%, gel when used for hemostasis.
DESIGN, SETTING, AND PARTICIPANTS
In this case series from a private practice (Hollywood Dermatology), 2 patients presented for dermatologic procedures, complicated by persistent bleeding.
INTERVENTIONS Patients were treated with 10 g of brimonidine, 0.33%, gel applied under occlusion for hemostasis.
MAIN OUTCOMES AND MEASURES Mental status, cardiopulmonary function.
RESULTS Both patients experienced deterioration of mental status, respiratory depression, and somnolence. Results from cardiac testing, laboratory workup, and imaging were negative for cardiac or neurologic etiology. Both patients improved in less than 24 hours.
CONCLUSIONS AND RELEVANCE Topical brimonidine, 0.33%, gel can result in systemic central nervous system toxic effects when used as a hemostatic agent. At present, it is not possible to define a quantity with which brimonidine can be used safely, nor can a safe wound size be defined. We, therefore, urge against the use of topical brimonidine as a hemostatic agent until its safety is further investigated.
In the emergency department, the patient had a Glasgow coma score of 3 and required intubation. Computed tomographic (CT) and magnetic resonance (MRI) scans revealed only age-related diffuse white matter changes. All laboratory results, including a comprehensive metabolic panel, complete blood cell count, and cardiac troponins, were within normal limits. The patient was successfully extubated at 12 hours, and his mental status returned to baseline at 18 hours.
Case 2
A man in his 90s presented for electrodessication and curettage of a large, inflamed, and painful actinic keratosis with an adjacent seborrheic keratosis on his left sideburn. The patient had persistent bleeding despite electrodessication. Ten grams of brimonidine, 0.33%, gel were applied under occlusion with telfa and gauze. Approximately 1 hour later, he developed altered mental status. He was taken to the emergency department, where results from an extensive workup, including CT, MRI, and laboratory investigation, were unremarkable. Altered mental status improved within 24 hours.
Discussion
Brimonidine, 0.33%, gel is a selective α-2 AR agonist approved by the US Food and Drug Administration in 2013 for the treatment of persistent facial erythema of rosacea in adults 18 years or older.
1 Brimonidine activates α-2 ARs present on the vascular smooth muscle, causing vasoconstriction of cutaneous vessels. 5 In an in vitro study, 6 brimonidine was found to be 5 times more potent than oxymetazoline in causing vasoconstriction of subcutaneous arteries and veins smaller than 200 μm in diameter.
The most common complication of dermatologic surgery is bleeding, which can result in hematoma formation, wound dehiscence, and infection. 7 Commonly used hemostatic agents include the addition of epinephrine to local anesthetic, electrosurgery, mechanical pressure, special suturing techniques, and gel foam. 7 Nevertheless, persistent bleeding occasionally poses a challenge. The use of topical vasoconstrictors as hemostatic agents has been described in endoscopic nasal and sinus surgery and in ophthalmology. 2, 3 Specifically, the use of diluted brimonidine prior to LASIK eye surgery has been shown to reduce discomfort and postoperative hemorrhage. 3 To that end, Schleichert and Weiss 4 described the use of topical brimonidine, 0.33%, gel in controlling mild postoperative bleeding after MMS. The use of topical vasoconstrictors as hemostatic agents is limited by their systemic toxic effects. A systematic review of the nasosinal surgery literature revealed many case reports of myocardial infarctions (MIs) and tachyarrhythmias after the use of topical phenylephrine and cocaine. 2 Epinephrine is considered a safer choice; however, reports of cardiogenic shock, MIs, and tachyarrhythmias have been published as well. 2 In a study comparing the systemic effects of topical epinephrine in patients with burns compared with patients without burns when undergoing skin grafting, patients with burns experienced elevated hearts rates and epinephrine and lactate levels compared with patients without burns. 8 Recently, a case of life-threatening brimonidine toxicity was reported in a 2-month-old girl who was being treated with a combination of brimonidine, 0.2%, and timolol, 0.5%, for an ulcerated hemangioma. The patient developed CNS depression and apnea that required intubation and mechanical ventilation with normalization of respiratory and neurologic function within 7 hours. 9 Kiryazov et al 10 reported 2 cases of CNS depression in infants being treated for congenital glaucoma. Both infants were being treated with topical brimonidine and brinzolamide, whereas the second infant also received topical timolol. There have been many other reports of CNS depression in infants receiving topical brimonidine therapy with symptoms, including apnea, respiratory depression, bradycardia, coma, somnolence, and hypotonia. 10, 11 Brimonidine is highly lipophilic and, therefore, easily crosses the bloodbrain barrier and can result in CNS toxic effects. This is a particular concern in infants in whom the blood-brain barrier has yet to fully mature. 10 We suspect that in both of the cases reported herein, the patients experienced altered mental status secondary to brimonidine toxic effects. In both cases, the procedure was performed at similar sites: the right temple and left sideburn, respectively. It is possible that owing to the location and the application of brimonidine directly to an open wound, brimonidine was able to cross the blood-brain barrier leading to CNS depression manifesting as altered mental status, respiratory failure, and somnolence. We propose that similar to the increased toxic effects secondary to topical epinephrine in patients with burns, 8 applying brimonidine to an open wound results in higher systemic concentration. In addition, we suspect that the quantity used contributed to the toxic effects because we have previously used smaller quantities safely. Furthermore, an additive effect with other CNS depressants, such as alcohol and opiates, could have potentiated the CNS toxic effects; however, there was no evidence of this in either case. 1 Finally, brimonidine is metabolized in the liver and excreted in the kidneys, but both patients had normal liver and kidney function. 
Key Points
Question Does the use of topical brimonidine, 0.33%, gel as a hemostatic agent pose a risk for central nervous system (CNS) depression?
Findings We describe 2 patients who presented to dermatology practice for dermatologic procedures complicated by persistent bleeding. Both patients experienced altered mental status and respiratory depression after the application of brimonidine, 0.33%, gel.
Meaning Topical brimonidine, 0.33%, gel may cause CNS depression when used as a hemostatic agent. Safe criteria for the use of brimonidine as hemostatic agents are unknown. We therefore discourage the use of topical brimonidine for hemostasis until its safety is further studied.
Alternatively, cardiogenic toxic effects and arrhythmias secondary to brimonidine toxic effects manifesting as faintness, loss of consciousness, or apnea should be considered.
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This is unlikely; however, considering the negative cardiac workup, although transient bradycardia cannot be ruled out. Finally, one must also consider cerebral air embolism. This complication, however, has only been described once as a complication of dermatologic surgery 13 and is less likely to explain the presentation in both cases, considering the use of brimonidine.
Limitations
The study is limited by its small sample size. It is also limited by the inability to isolate all possible confounding causes of CNS depression. Therefore, a definitive relationship between topical brimonidine, 0.33%, gel and CNS depression cannot be established.
Conclusions
Topical brimonidine, 0.33%, gel can result in systemic CNS toxic effect when used as a hemostatic agent. At present, it is not possible to define a quantity with which brimonidine can be used safely, nor can a safe wound size be defined. This may be further complicated when used in combination with other CNS depressants or by the patient's liver or kidney function. We, therefore, urge against the use of topical brimonidine as a hemostatic agent until its use is further investigated.
